Market Closed -
Nasdaq
21:30:00 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
13.98
USD
|
+5.51%
|
|
+18.37%
|
-22.81%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
806.1
|
486.5
|
942.5
|
1,085
|
843.3
|
-
|
-
|
Enterprise Value (EV)
1 |
806.1
|
486.5
|
621.3
|
600.5
|
481.3
|
466.4
|
554.6
|
P/E ratio
|
-11.7
x
|
-4.98
x
|
-6.57
x
|
-6.59
x
|
-4.24
x
|
-3.87
x
|
-3.63
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.3
x
|
64.3
x
|
97.3
x
|
687
x
|
547
x
|
145
x
|
254
x
|
EV / Revenue
|
19.3
x
|
64.3
x
|
64.1
x
|
380
x
|
312
x
|
80.2
x
|
167
x
|
EV / EBITDA
|
-
|
-
|
-4.96
x
|
-3.29
x
|
-2.21
x
|
-1.9
x
|
-1.91
x
|
EV / FCF
|
-20.8
x
|
-6.29
x
|
-6.45
x
|
-5.12
x
|
-2.75
x
|
-2.39
x
|
-2.4
x
|
FCF Yield
|
-4.81%
|
-15.9%
|
-15.5%
|
-19.5%
|
-36.4%
|
-41.8%
|
-41.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,480
|
36,039
|
48,759
|
59,896
|
60,319
|
-
|
-
|
Reference price
2 |
22.72
|
13.50
|
19.33
|
18.11
|
13.98
|
13.98
|
13.98
|
Announcement Date
|
16/03/21
|
28/02/22
|
09/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
41.82
|
7.572
|
9.685
|
1.58
|
1.541
|
5.814
|
3.325
|
EBITDA
1 |
-
|
-
|
-125.4
|
-182.3
|
-218.1
|
-245.9
|
-290.3
|
EBIT
1 |
-41.64
|
-19.99
|
-127.2
|
-184.1
|
-209.5
|
-244.3
|
-275.2
|
Operating Margin
|
-99.59%
|
-263.95%
|
-1,313.37%
|
-11,654.75%
|
-13,593.27%
|
-4,202.35%
|
-8,275.81%
|
Earnings before Tax (EBT)
1 |
-41.53
|
-19.71
|
-123.3
|
-161.3
|
-203.2
|
-246.7
|
-276.1
|
Net income
1 |
-41.53
|
-19.71
|
-123.3
|
-161.3
|
-201.1
|
-240.6
|
-270.9
|
Net margin
|
-99.32%
|
-260.35%
|
-1,273.32%
|
-10,211.14%
|
-13,048.61%
|
-4,138.03%
|
-8,147.07%
|
EPS
2 |
-1.950
|
-2.710
|
-2.940
|
-2.750
|
-3.294
|
-3.612
|
-3.849
|
Free Cash Flow
1 |
-38.8
|
-77.4
|
-96.39
|
-117.3
|
-175.2
|
-195.2
|
-230.9
|
FCF margin
|
-92.79%
|
-1,022.13%
|
-995.26%
|
-7,422.91%
|
-11,363.63%
|
-3,357.46%
|
-6,944.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/21
|
28/02/22
|
09/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.61
|
1.999
|
1.249
|
4.989
|
1.482
|
1.965
|
1.332
|
0.248
|
-
|
-
|
0.3871
|
0.3871
|
0.3871
|
0.6371
|
0.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-50
|
-53
|
-58
|
-63
|
-
|
EBIT
1 |
-27.11
|
-24.6
|
-28.21
|
-29.64
|
-31.95
|
-37.4
|
-42.1
|
-47.33
|
-47.68
|
-47.04
|
-49.06
|
-51.49
|
-53.89
|
-56.03
|
-61.05
|
Operating Margin
|
-1,684.04%
|
-1,230.57%
|
-2,258.69%
|
-594.15%
|
-2,155.67%
|
-1,903.31%
|
-3,160.29%
|
-19,083.87%
|
-
|
-
|
-12,674.71%
|
-13,303.39%
|
-13,922.92%
|
-8,794.21%
|
-12,210.5%
|
Earnings before Tax (EBT)
1 |
-27.04
|
-24.53
|
-28.1
|
-29.55
|
-30.62
|
-35.06
|
-37.55
|
-41.19
|
-41.49
|
-41.11
|
-46.67
|
-49.74
|
-52.55
|
-54.9
|
-59.06
|
Net income
1 |
-27.04
|
-24.53
|
-28.1
|
-29.55
|
-30.62
|
-35.06
|
-37.55
|
-41.19
|
-41.49
|
-41.11
|
-46.47
|
-49.19
|
-51.78
|
-53.61
|
-59.06
|
Net margin
|
-1,679.81%
|
-1,227.16%
|
-2,249.8%
|
-592.22%
|
-2,065.79%
|
-1,784.22%
|
-2,818.92%
|
-16,609.68%
|
-
|
-
|
-12,006.02%
|
-12,708.34%
|
-13,376.65%
|
-8,415.71%
|
-11,812%
|
EPS
2 |
-0.7500
|
-0.6800
|
-0.7800
|
-0.8200
|
-0.6500
|
-0.7200
|
-0.6700
|
-0.7000
|
-0.7000
|
-0.6900
|
-0.7746
|
-0.8124
|
-0.8480
|
-0.8764
|
-0.8450
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
28/02/22
|
09/05/22
|
08/08/22
|
08/11/22
|
09/03/23
|
09/05/23
|
09/08/23
|
09/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
321
|
484
|
362
|
377
|
289
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-38.8
|
-77.4
|
-96.4
|
-117
|
-175
|
-195
|
-231
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-48.1%
|
-41%
|
-52.1%
|
-59.9%
|
-76.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-43.1%
|
-37.4%
|
-51.9%
|
-61.2%
|
-81.5%
|
Assets
1 |
-
|
-
|
285.9
|
431.4
|
387.7
|
392.9
|
332.4
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.53
|
1.95
|
1.76
|
0.92
|
0.2
|
1.98
|
2.43
|
Capex / Sales
|
3.66%
|
25.79%
|
18.17%
|
58.29%
|
12.97%
|
33.97%
|
72.98%
|
Announcement Date
|
16/03/21
|
28/02/22
|
09/03/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
13.98
USD Average target price
43
USD Spread / Average Target +207.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.81% | 843M | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|